Press Releases

Epic Sciences to Present at UBS Global Healthcare Conference

SAN DIEGO, May 14, 2015 -- Epic Sciences, Inc. ("Epic"), a private biotech company that designs and develops diagnostics to personalize and advance the treatment and management of cancer, announced today that Michael Rodriguez, chief financial officer,…

Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells

SAN DIEGO, April 16, 2015 /PRNewswire/ -- Epic Sciences announced today that its no cell left behind™technology has successfully integrated single cell isolation and downstream genetic analysis of circulating tumor cells (CTCs) to the platform's…

Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

SAN DIEGO – March 9, 2015 – Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in prostate cancer, announced today they have entered into a collaboration to apply…

Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference

SAN DIEGO, Feb. 26, 2015 /PRNewswire/ — Epic Sciences announced today that President and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. EST in the MIT Room, 3rd…

Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

SAN DIEGO, Feb. 25, 2015 /PRNewswire/ -- Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing…

Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

SAN DIEGO, Feb. 23, 2015 /PRNewswire/ -- Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic's…

Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers

SAN DIEGO – January 26, 2015 – Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Personalized Medicine World…

Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory

SAN DIEGO – January 8, 2015 – Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human…

Epic Sciences to Present at the Piper Jaffray Healthcare Conference

SAN DIEGO and NEW YORK CITY – November 26, 2014 – Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, will present at the 26th Annual Piper Jaffray…

Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies at the 26th EORTC-NCI-AACR Symposium

SAN DIEGO and BARCELONA, Spain, Nov. 17, 2014 -- Epic Sciences will present data describing the detection of clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating…